Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Icovamenib - Biomea Fusion

Next Previous
X
Search
Drug Profile

Icovamenib - Biomea Fusion

Alternative Names: BMF-219; Covalent menin inhibitor - Biomea Fusion

Latest Information Update: 26 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biomea Fusion
  • Class Antihyperglycaemics; Antineoplastics; Morpholines; Piperidines; Pyridines; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Menin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Phase I Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Colorectal cancer; Diffuse large B cell lymphoma; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours

Most Recent Events

  • 18 Nov 2024 Biomea Fusion plans a end-of-phase II meeting with the US FDA to discuss late-stage development program for Type-2 diabetes mellitus in 2025
  • 18 Nov 2024 Updated efficacy data from the phase I/II COVALENT-111 trial in Type-2 diabetes mellitus released by Biomea Fusion
  • 30 Oct 2024 Biomea Fusion plans a phase II COVALENT-211 trial for Diabetes mellitus (Combination therapy) in 2025 (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top